Avacta Group plc - To Present at BioTrinity 2017

02 May 2017

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at BioTrinity 2017, Europe's leading Biopartnering and Investment Conference, to be held on 9-10 May at the Novotel  London West.

Founded and produced by OBN, BioTrinity is now in its 11th year. BioTrinity continues to grow with more than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms expected to attend.

Avacta's Chief Executive, Alastair Smith, will be presenting in the Company Showcase Therapeutics Track at 1440 in the Alsace Room. The Company will also be exhibiting at stand 44.

ENDS

NOTES

For further information from Avacta Group plc, please contact: 

Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane - Corporate Broking

WG Partners
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang

Tel: +44 (0) 207 220 0500

www.finncap.com

 
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
www.wgpartners.co.uk 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

FTI Consulting (Financial Media and IR)
Simon Conway / Natalie Garland-Collins

Tel: +44 (0)7787 502 947

katie.odgaard@zymecommunications.com

Tel: +44 (0) 203 727 1000
avacta@fticonsulting.com

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

About OBN

OBN is the Membership organisation supporting and bringing together the UK's innovative life sciences companies, corporate partners and investors. Our 400-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities.  OBN is best known for its delivery of BioTrinity (11th edition: May 9-10, 2017), Europe's leading life sciences investment and biopartnering conference, visit www.biotrinity.com for more information.